Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

BSH/ISH 2016 View overview page

2:21
Precision medicine for MDS, what drugs for which patients?
David Steensma • 18 Apr 2016
2:35
How molecular testing guides treatment in AML
Gail Roboz • 18 Apr 2016
2:16
The utility of next-generation sequencing for multiple myeloma
Chng W. Joo • 18 Apr 2016
2:29
SPIRIT2 trial on dasatinib for AML – safety and side effect management
Stephen O’Brien • 18 Apr 2016
1:07
Moving towards personalized therapy for AML
Nigel Russell • 18 Apr 2016
1:04
New approaches to treat myeloid neoplasms
David Steensma • 18 Apr 2016
1:21
The role of transplant in the era of new treatments for lymphoma and CLL
Peter Dreger • 18 Apr 2016
2:38
How to treat difficult forms of MDS
David Steensma • 18 Apr 2016
1:18
Key recurrent mutations in MDS
David Steensma • 18 Apr 2016
1:46
Application of molecular genetic testing in AML
Gail Roboz • 18 Apr 2016
2:14
Next steps for advancing the molecular stratification of CLL
Anna Schuh • 18 Apr 2016
4:32
Understanding the drivers behind disease with the 100,000 Genomes Project
Mark Caulfield • 18 Apr 2016
1:33
A registry for AML in pregnancy – why it is important
Sahra Ali • 18 Apr 2016
2:39
How the frailty score help guide treatment of older multiple myeloma patients
Sonja Zweegman • 18 Apr 2016
2:21
How to manage AML in pregnancy
Sahra Ali • 18 Jun 2016
3:07
The differences between biological and chronological age, with their implications on AML treatment
Charles Craddock • 20 Apr 2016
The content of VJHemOnc is intended for healthcare professionals